Wall Street brokerages predict that Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) will post earnings of ($2.74) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Biohaven Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($2.42) and the lowest estimate coming in at ($3.04). Biohaven Pharmaceutical posted earnings of ($2.04) per share during the same quarter last year, which would suggest a negative year over year growth rate of 34.3%. The firm is scheduled to issue its next earnings results on Friday, November 6th.
On average, analysts expect that Biohaven Pharmaceutical will report full-year earnings of ($11.94) per share for the current financial year, with EPS estimates ranging from ($12.45) to ($11.03). For the next financial year, analysts expect that the firm will post earnings of ($8.75) per share, with EPS estimates ranging from ($10.55) to ($7.44). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Biohaven Pharmaceutical.
Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings data on Monday, August 10th. The company reported ($2.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.78) by $0.23. The business had revenue of $9.70 million during the quarter, compared to the consensus estimate of $7.43 million. During the same period last year, the company posted ($2.35) earnings per share.
In other Biohaven Pharmaceutical news, Director Gregory Bailey sold 24,566 shares of the stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $79.47, for a total value of $1,952,260.02. Following the completion of the sale, the director now owns 2,559,161 shares in the company, valued at approximately $203,376,524.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John W. Childs purchased 6,678 shares of the business’s stock in a transaction on Friday, September 11th. The stock was acquired at an average price of $59.00 per share, with a total value of $394,002.00. Following the purchase, the director now directly owns 2,508,616 shares in the company, valued at approximately $148,008,344. The disclosure for this purchase can be found here. Insiders sold a total of 63,097 shares of company stock valued at $4,932,283 over the last 90 days. 19.10% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the business. Point72 Hong Kong Ltd purchased a new stake in Biohaven Pharmaceutical in the 2nd quarter worth $73,000. PNC Financial Services Group Inc. increased its stake in Biohaven Pharmaceutical by 6,251.9% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,715 shares of the company’s stock worth $124,000 after buying an additional 1,688 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Biohaven Pharmaceutical by 237.0% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,820 shares of the company’s stock worth $118,000 after buying an additional 1,280 shares in the last quarter. UBS Group AG increased its stake in Biohaven Pharmaceutical by 69.3% in the 2nd quarter. UBS Group AG now owns 1,943 shares of the company’s stock worth $142,000 after buying an additional 795 shares in the last quarter. Finally, First Mercantile Trust Co. purchased a new stake in Biohaven Pharmaceutical in the 2nd quarter worth $157,000. Institutional investors and hedge funds own 98.73% of the company’s stock.
BHVN traded down $1.07 during mid-day trading on Friday, reaching $77.40. 5,819 shares of the company traded hands, compared to its average volume of 791,994. The stock has a market capitalization of $4.68 billion, a P/E ratio of -7.11 and a beta of 1.19. The company’s fifty day moving average price is $69.56 and its 200-day moving average price is $62.92. Biohaven Pharmaceutical has a 52-week low of $26.56 and a 52-week high of $80.00.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.